Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6284539

Title:Method for generating dopaminergic cells derived from neural precursors
Inventors:Bowen, David C.; Washington, DC, USA
Summary:This invention introduces a novel process for the production of cells that express tyrosine hydroxylase, via the transformation of central nervous system stem cells with a transcriptional regulator.. Described herein are methods by which the differentiation of multipotential precursor cells from the central nervous system may be directed, such that the gene coding for the nuclear receptor, Nurr1, is introduced into the central nervous system (CNS) stem cells, thereby causing the cells to adopt a dopaminergic cell fate. Therapeutic applications include the treatment of injured or degenerate dopaminergic cells, such as in Parkinson's Disease or other neurological disorders.
Abstract:The present invention describes a novel method to direct a particular set of fate choice decisions by multipotential precursor cells from the central nervous system. Specifically we show that introducing the gene coding for the nuclear receptor, Nurr1, into central nervous system (CNS) stem cells causes cells to adopt a dopaminergic cell fate. One use of this technology would be to prepare in vitro neural populations enriched in dopaminergic cells for transplantation in Parkinson's Disease or other neurological disorders. Furthermore, the finding that Nurr1 expression induces a dopaminergic phenotype suggests that introducing this gene into the brains of patients in which dopaminergic cells are degenerating or have been injured may promote the functional recovery of these neurons and thus the clinical recovery of the patient. Finally, the technology described in this application could be incorporated into a program of drug screening or gene discovery.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6284539
Application Number:US1998000169309
Date Filed:09/10/1998
Date Published:04/09/2001
Assignee:NeuralStem Biopharmaceuticals, Ltd., College Park, MD, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/13/2021